Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03127605
Previous Study | Return to List | Next Study

Inotuzumab Ozogamicin - PF-05208773

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03127605
Expanded Access Status : Available
First Posted : April 25, 2017
Last Update Posted : September 17, 2018
Sponsor:
Information provided by (Responsible Party):
Pfizer

Tracking Information
First Submitted Date April 20, 2017
First Posted Date April 25, 2017
Last Update Posted Date September 17, 2018
 
Descriptive Information
Brief Title Inotuzumab Ozogamicin - PF-05208773
Official Title Not Provided
Brief Summary

Information relating to requesting compassionate access for this investigational drug can be found at the following link:

http://www.pfizer.com/research/compassionate_use

Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Individual Patients
Condition Not Provided
Intervention Drug: Inotuzumab Ozogamicin
Other Name: PF-05208773
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status Available
Eligibility Criteria

Inclusion Criteria:

-

Exclusion Criteria:

-

Sex/Gender Not Provided
Ages Child, Adult, Older Adult
Contacts
Contact: Pfizer CAReS 1-800-718-1021 PfizerCAReS@pfizer.com
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT03127605
Other Study ID Numbers B193
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators Not Provided
PRS Account Pfizer
Verification Date September 2018